THOUSAND OAKS, Calif., April 10, 2014 /PRNewswire/ -- Ceres, Inc. (Nasdaq: CERE), an agricultural biotechnology and seed company, announced today financial results for the three months ended February 28, 2014 and provided an update on its business in Brazil.

The company reported that harvests for the 2013-2014 sorghum growing season in Brazil have commenced, with the majority of locations to be harvested over the next four to six weeks as various products reach maturity. Since the favorable start to the season, weather patterns in South-Central Brazil have been variable and drier than normal overall, with severely dry and hot conditions affecting several of the company's sorghum evaluation areas, most notably in western Sao Paulo state. The impact of variable weather has been ameliorated, in part, by the geographic distribution of the evaluation sites and the natural tolerance of sorghum to harsh conditions. At this time, the company expects to generate reliable yield and performance data at enough locations to select products for advanced field evaluations next season.

"With new hybrids moving forward in our pipeline, we are confident that we can continue to drive yields higher for our mill customers and address the industry's need for additional feedstock supply," said Richard Hamilton, President and Chief Executive Officer of Ceres.

The company has previously indicated that it plans to use this growing season and the next to demonstrate the field performance of its sweet and high-biomass sorghum product lines, which can be used to produce ethanol or combusted for electricity generation, respectively.

Ceres Chief Financial Officer Paul Kuc reported that expenses for the quarter were generally in line with management's expectations, and benefited from cost-saving measures initiated in the first fiscal quarter. "With the successful completion of our follow-on equity offering last month, we have strengthened our balance sheet and have the resources we need to launch new seed products as well as pursue additional out-licensing opportunities for our biotech traits and genetic technologies," said Kuc.

Recent Business Highlights




    --  Ceres' sorghum field evaluations this season in Brazil have been managed
        overall according to the company's recommended crop management
        protocols, with variations among locations and hybrids primarily due to
        differences in growing conditions during the season as well as
        anticipated variations in the adaptation range of individual hybrids
        under evaluation. At this time, approximately 40 customer evaluation
        sites are expected to provide yield and performance data. Based on
        visual inspections of plant health, size and populations per hectare,
        company agronomists estimate that approximately 65% of these locations
        are in good to excellent condition and 35% are in fair condition. Due
        primarily to severe conditions in certain regions, approximately 15
        customer evaluation sites are not expected to provide meaningful yield
        data or have been lost. Plantings primarily consist of multi-hybrid
        evaluations designed to determine yield potential, identify the best
        performing hybrids for specific regions and demonstrate crop management
        practices. Assessments of individual evaluation locations are subject to
        change until harvests are completed. The company expects to collect
        yield results by July.


    --  Ceres has advanced its high sugar trait for evaluation in
        commercial-type sweet sorghum hybrids. This biotech trait significantly
        boosted sugar yields in non-commercial types of sorghum during field
        evaluations last year. The company has planned both field and greenhouse
        evaluations this year. Field trials for Ceres' other biotech traits are
        also planned in both rice and corn, with results expected by the end of
        this year, provided that necessary field trial permits are issued in a
        timely manner.
    --  On March 10, 2014, Ceres completed an underwritten public offering,
        issuing 23,000,000 shares of common stock at $1.00 per share, including
        3,000,000 shares issued pursuant to the exercise in full of the
        underwriters' option to purchase additional shares to cover
        over-allotments. Net proceeds, after deducting underwriting discounts,
        commissions and estimated offering expenses, were $20.8 million.

Second Quarter Financial Results

Total revenues for the quarter ended February 28, 2014 were $0.5 million compared to $1.0 million for the quarter ended February 28, 2013. The change was primarily due to a decrease in collaborative research and government grant revenue. Product sales remained relatively unchanged compared to the second quarter of 2013.

Cost of product sales decreased by $1.7 million to $0.6 million for the three months ended February 28, 2014 compared to the same period in the prior year. The decrease was primarily due to reduced expenses of $1.1 million for obsolete seed inventory and reduced expenses of $0.6 million resulting from changes and reductions in the company's sales incentive and promotional programs in Brazil.

Research and development expenses decreased by $0.8 million to $3.6 million for the three months ended February 28, 2014 compared to the same period in the prior year. In the U.S., research and development expenses decreased by $0.9 million primarily due to reduced personnel and related expenses and reduced external research and development expenses. In Brazil, research and development expenses increased by $0.1 million primarily as a result of increased personnel and related expenses.

Selling, general and administrative expenses increased by $0.2 million to $3.6 million for the three months ended February 28, 2014 compared to the same period in the prior year. In the U.S., expenses decreased by $0.6 million due to reduced personnel and related expenses and reduced professional fees and patent expenses. The reduction in the U.S. was offset by an increase in Brazil of $0.8 million primarily for personnel and related expenses.

For the quarter ended February 28, 2014, Ceres reported a net loss of $7.2 million, or $0.29 per share, compared to a net loss of $9.0 million, or $0.36 per share, for the quarter ended February 28, 2013.

At February 28, 2014, cash and cash equivalents and marketable securities totaled $18.3 million.

Conference Call and Webcast Information
Ceres has scheduled a conference call for 4:30 p.m. EDT (1:30 p.m. PDT) today to discuss its fiscal second quarter results and to provide an update on its business. The webcast of the conference call may be accessed at investor.ceres.net. Audio of the teleconference is also available by dialing:

North America callers:
(877) 838-4153

International callers:
+1 (720) 545-0037

An audio replay of the call will be available two hours after the conclusion of the live call, and remain available on the Ceres website for 30 days.

About Ceres
Ceres, Inc. is an agricultural biotechnology company that markets seeds for energy crops used in the production of renewable transportation fuels, electricity and bio-based products. The company combines advanced plant breeding and biotechnology to develop products that can address the limitations of first-generation bioenergy feedstocks, increase biomass productivity, reduce crop inputs and improve cultivation on marginal land. Its development activities include sweet sorghum, high-biomass sorghum, switchgrass and miscanthus. Ceres markets its products under its Blade brand.

Ceres Forward-Looking Statements
This press release may contain forward-looking statements. All statements, other than statements of historical facts, including statements regarding Ceres' efforts to develop and commercialize its products,
anticipated yields and product performance, status of crop plantings, short-term and long-term business strategies, market and industry expectations, future operating metrics, and future results of operations and financial position, including anticipated cost savings from the company's plan to align expenditures, are forward-looking statements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Ceres' control. Factors that could materially affect actual results can be found in Ceres' filings with the U.S. Securities and Exchange Commission. Ceres undertakes no obligation to update publicly, except to the extent required by law, any forward-looking statements for any reason after the date the company issues this press release to conform these statements to actual results or to changes in the company's expectations.


                             CERES, INC. AND SUBSIDIARY

                  Condensed Consolidated Statements of Operations

                 (In thousands, except share and per share amounts)

                                    (Unaudited)


                                               Three Months Ended           Six Months Ended
                                                February 28,             February 28,
                                                ------------             ------------

                                                2014           2013        2014           2013
                                                ----           ----        ----           ----


    Revenues:

      Product sales                              $46            $59         $66            $73

      Collaborative
       research and
       government
       grants                                    449            967       1,192          2,918
                                                 ---            ---       -----          -----

           Total revenues                        495          1,026       1,258          2,991
                                                 ---          -----       -----          -----

    Cost and operating expenses:

      Cost of
       product sales                             556          2,280       1,865          2,980

      Research and
       development                             3,570          4,368       7,984          8,711

      Selling,
       general and
       administrative                          3,585          3,392       6,845          7,236
                                               -----          -----       -----          -----

          Total cost and
           operating
           expenses                            7,711         10,040      16,694         18,927
                                               -----         ------      ------         ------

    Loss from
     operations                               (7,216)        (9,014)    (15,436)       (15,936)

    Interest
     expense                                     (19)            (1)        (19)            (1)

    Interest
     income                                       10             49          26             78
                                                 ---            ---         ---            ---

    Loss before
     income taxes                             (7,225)        (8,966)    (15,429)       (15,859)

    Income tax
     expense                                       -              -          (1)            (1)
                                                 ---            ---         ---            ---

    Net loss                                 $(7,225)       $(8,966)   $(15,430)      $(15,860)
                                             =======        =======    ========       ========

    Basic and
     diluted net
     loss per
     share                                    $(0.29)        $(0.36)     $(0.61)        $(0.64)

    Weighted average outstanding common
     shares used for net loss per share:

        Basic and
         diluted                          25,205,258     24,801,986  25,155,702     24,747,344


                                            CERES, INC. AND SUBSIDIARY

                                       Condensed Consolidated Balance Sheets

                                (In thousands, except share amounts and par value)

                                                    (Unaudited)


                                                       February 28,                   August 31,
                                                       ------------                   ----------

                                                                       2014                        2013
                                                                       ----                        ----


    Assets

    Current assets:

      Cash and cash
       equivalents                                                   $5,448                      $8,881

      Marketable
       securities                                                    12,883                      21,630

      Prepaid
       expenses                                                         541                         791

      Accounts
       receivable                                                       761                         957

      Inventories                                                         -                          20

      Deferred
       offering
       costs                                                            625                           -

      Other current
       assets                                                           154                         157
                                                                        ---                         ---

        Total current
         assets                                                      20,412                      32,436

    Property and
     equipment,
     net                                                              4,429                       4,633

    Other assets                                                         44                         109
                                                                        ---                         ---

        Total assets                                                $24,885                     $37,178
                                                                    =======                     =======


    Liabilities and Stockholders' Equity

    Current liabilities:

      Accounts
       payable and
       accrued
       expenses                                                      $4,804                      $3,825

      Other current
       liabilities                                                      351                          18

      Current
       portion of
       long-term
       debt                                                             109                         154
                                                                        ---                         ---

        Total current
         liabilities                                                  5,264                       3,997

    Other non-
     current
     liabilities                                                         84                          93

    Long-term
     debt, net of
     current
     portion                                                             44                          82

       Total
        liabilities                                                   5,392                       4,172
                                                                      -----                       -----

    Commitments and contingencies

    Stockholders' equity:

      Common stock
       and                                       shares issued                  2013.
       additional                                and
       paid in                                   outstanding
       capital,                                  at February
       $0.01 par                                 28, 2014;
       value;                                    24,897,199
       490,000,000                               shares issued
       shares                                    and
       authorized;                               outstanding
       25,204,602                                                   310,154                     308,286

      Accumulated
       other
       comprehensive
       loss                                                            (647)                       (696)

      Accumulated
       deficit                                                     (290,014)                   (274,584)
                                                                   --------                    --------

        Total
         stockholders'
         equity                                                      19,493                      33,006
                                                                     ------                      ------

          Total
           liabilities
           and
           stockholders'
           equity                                                   $24,885                     $37,178
                                                                    =======                     =======

SOURCE Ceres, Inc.